William Gay
Family Medicine · Beattyville, KYNPI 1699071480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,199 and has fallen 56.3% since, to $523 in 2025.
Across 266 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$805
- Amgen$659
- AbbVie$327
- Boehringer Ingelheim$222
- Astellas Pharma US Inc$216
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,45598%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,042 |
| GSK | 44 | $805 |
| Amgen | 39 | $659 |
| AbbVie(2 entities) | 18 | $327 |
| Boehringer Ingelheim | 20 | $222 |
| Astellas Pharma US Inc | 11 | $216 |
| Bayer | 12 | $204 |
| Lilly USA, LLC | 9 | $160 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $158 |
| Grifols USA, LLC | 6 | $142 |
| Novartis | 8 | $119 |
| Merck | 12 | $117 |
| Johnson & Johnson | 5 | $91 |
| Amarin Pharma, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Pfizer | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$210
How this compares
$4,551 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 130 | $163,285 |
| OzempicSemaglutide | 142 | $151,158 |
| EliquisApixaban | 150 | $133,489 |
| FarxigaDapagliflozin Propanediol | 147 | $116,632 |
| OtezlaApremilast | 20 | $96,261 |
| JardianceEmpagliflozin | 107 | $92,919 |
| Repatha SureclickEvolocumab | 128 | $86,676 |
| XifaxanRifaximin | 24 | $77,408 |
| Ondansetron Hcl | 133 | $74,719 |
| JanuviaSitagliptin Phosphate | 52 | $63,996 |
| LinzessLinaclotide | 88 | $51,725 |
| XareltoRivaroxaban | 41 | $50,268 |
| MyrbetriqMirabegron | 49 | $39,361 |
| TrulicityDulaglutide | 27 | $38,906 |
| VraylarCariprazine Hcl | 27 | $38,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $160 | $202,191157 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $222 | $166,323228 claims |
| PfizerEliquis, Nurtec Odt | $50 | $164,026169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,042 | $155,468220 claims |
| AbbVieLinzess, Vraylar, Namzaric | $327 | $103,768131 claims |
| AmgenOtezla | $659 | $96,26120 claims |
| MerckJanuvia, Janumet, Dulera | $117 | $90,61389 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Invokana | $91 | $82,12364 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $56 | $77,40824 claims |
| GSKTrelegy Ellipta, Shingrix | $805 | $41,43764 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $39,36149 claims |
| NovartisEntresto | $119 | $26,74625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Beattyville
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
- Derek JonesAshland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.